Exploring Novel Methods for Modulating Tumor Blood Vessels in Cancer Treatment

Current Biology

Volumn 26, Issue 21, 2016, Pages R1161-R1166

  Wong, Ping Pui ^a   Bodrug, Natalia ^a   Hodivala Dilke, Kairbaan M ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; HUMAN; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY;

HUMANS; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 84994414361     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cub.2016.09.043     Document Type: Review

References (50)

1. 1 Folkman, J., Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 6 (2007), 273–286.
2. 2 Chung, A.S., Lee, J., Ferrara, N., Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 10 (2010), 505–514.
3. 3 Desgrosellier, J.S., Cheresh, D.A., Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10 (2010), 9–22.
4. 4 Folkman, J., Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 285 (1971), 1182–1186.
5. 5 Okines, A., Cunningham, D., Current perspective: bevacizumab in colorectal cancer–a time for reappraisal?. Eur. J. Cancer 45 (2009), 2452–2461.
6. 6 Giantonio, B.J., Catalano, P.J., Meropol, N.J., O'Dwyer, P.J., Mitchell, E.P., Alberts, S.R., Schwartz, M.A., Benson, A.B. 3rd, Cooperative, Eastern, Oncology Group Study, E., Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25 (2007), 1539–1544.
7. 7 Vasudev, N.S., Reynolds, A.R., Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17 (2014), 471–494.
8. 8 Bergers, G., Hanahan, D., Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8 (2008), 592–603.
9. 9 Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G., Kerbel, R.S., Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 (2009), 232–239.
10. 10 Paez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Vinals, F., Inoue, M., Bergers, G., Hanahan, D., Casanovas, O., Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 (2009), 220–231.
11. 11 Jain, R.K., Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26 (2014), 605–622.
12. 12 Carmeliet, P., Jain, R.K., Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10 (2011), 417–427.
13. 13 Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R.A., Schwartz, B., Simantov, R., Kelley, S., Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5 (2006), 835–844.
14. 14 Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S.T., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl. J. Med. 356 (2007), 115–124.
15. 15 Webb, T., Vascular normalization: study examines how antiangiogenesis therapies work. J. Natl. Cancer Inst. 97 (2005), 336–337.
16. 16 Kerbel, R.S., Tumor angiogenesis. New Engl. J. Med. 358 (2008), 2039–2049.
17. 17 Goel, H.L., Mercurio, A.M., VEGF targets the tumour cell. Nat. Rev. Cancer 13 (2013), 871–882.
18. 18 Neufeld, G., Kessler, O., Herzog, Y., The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF. Adv. Exp. Med. Biol. 515 (2002), 81–90.
19. 19 Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3 (2004), 391–400.
20. 20 Kerbel, R.S., Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. J. Mammary Gland Biol. Neoplasia 17 (2012), 229–239.
21. 21 Escudier, B., Eisen, T., Stadler, W.M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A.A., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl. J. Med. 356 (2007), 125–134.
22. 22 Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., de Oliveira, A.C., Santoro, A., Raoul, J.L., Forner, A., et al. Sorafenib in advanced hepatocellular carcinoma. New Engl. J. Med. 359 (2008), 378–390.
23. 23 Demetri, G.D., van Oosterom, A.T., Garrett, C.R., Blackstein, M.E., Shah, M.H., Verweij, J., McArthur, G., Judson, I.R., Heinrich, M.C., Morgan, J.A., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006), 1329–1338.
24. 24 D'Amato, R.J., Loughnan, M.S., Flynn, E., Folkman, J., Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91 (1994), 4082–4085.
25. 25 Vandekeere, S., Dewerchin, M., Carmeliet, P., Angiogenesis revisited: an overlooked role of endothelial cell metabolism in vessel sprouting. Microcirculation 22 (2015), 509–517.
26. 26 Eelen, G., de Zeeuw, P., Simons, M., Carmeliet, P., Endothelial cell metabolism in normal and diseased vasculature. Circ. Res. 116 (2015), 1231–1244.
27. 27 Verdegem, D., Moens, S., Stapor, P., Carmeliet, P., Endothelial cell metabolism: parallels and divergences with cancer cell metabolism. Cancer Metab., 2, 2014, 19.
28. 28 Schoors, S., De Bock, K., Cantelmo, A.R., Georgiadou, M., Ghesquiere, B., Cauwenberghs, S., Kuchnio, A., Wong, B.W., Quaegebeur, A., Goveia, J., et al. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 19 (2014), 37–48.
29. 29 Jain, R.K., Duda, D.G., Clark, J.W., Loeffler, J.S., Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature clinical practice. Oncology 3 (2006), 24–40.
30. 30 Van der Veldt, A.A., Lubberink, M., Bahce, I., Walraven, M., de Boer, M.P., Greuter, H.N., Hendrikse, N.H., Eriksson, J., Windhorst, A.D., Postmus, P.E., et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21 (2012), 82–91.
31. 31 Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M.L., Segura, I., Li, X., Knevels, E., et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19 (2011), 31–44.
32. 32 Qayum, N., Im, J., Stratford, M.R., Bernhard, E.J., McKenna, W.G., Muschel, R.J., Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo. Clin. Cancer. Res. 18 (2012), 161–169.
33. 33 Maes, H., Kuchnio, A., Peric, A., Moens, S., Nys, K., De Bock, K., Quaegebeur, A., Schoors, S., Georgiadou, M., Wouters, J., et al. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 26 (2014), 190–206.
34. 34 Agrawal, V., Maharjan, S., Kim, K., Kim, N.J., Son, J., Lee, K., Choi, H.J., Rho, S.S., Ahn, S., Won, M.H., et al. Direct endothelial junction restoration results in significant tumor vascular normalization and metastasis inhibition in mice. Oncotarget 5 (2014), 2761–2777.
35. 35 Noguera-Troise, I., Daly, C., Papadopoulos, N.J., Coetzee, S., Boland, P., Gale, N.W., Lin, H.C., Yancopoulos, G.D., Thurston, G., Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444 (2006), 1032–1037.
36. 36 Soler, A., Serra, H., Pearce, W., Angulo, A., Guillermet-Guibert, J., Friedman, L.S., Vinals, F., Gerhardt, H., Casanovas, O., Graupera, M., et al. Inhibition of the p110alpha isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. J. Exp. Med. 210 (2013), 1937–1945.
37. 37 Sonveaux, P., Provascular strategy: targeting functional adaptations of mature blood vessels in tumors to selectively influence the tumor vascular reactivity and improve cancer treatment. Radiother. Oncol. 86 (2008), 300–313.
38. 38 Wood, P.J., Hirst, D.G., Modification of tumour response by calcium antagonists in the SCVII/St tumour implanted at two different sites. Int. J. Radiat. Biol. 56 (1989), 355–367.
39. 39 Kaelin, W.G. Jr., Shrivastav, S., Shand, D.G., Jirtle, R.L., Effect of verapamil on malignant tissue blood flow in SMT-2A tumor-bearing rats. Cancer Res. 42 (1982), 3944–3949.
40. 40 Bergman, A.M., Pinedo, H.M., Talianidis, I., Veerman, G., Loves, W.J., van der Wilt, C.L., Peters, G.J., Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br. J. Cancer 88 (2003), 1963–1970.
41. 41 Ahmed, J.H., Elliott, H.L., Meredith, P.A., Reid, J.L., Low-dose verapamil in middle-aged and elderly patients with angina pectoris: no evidence of increased susceptibility to the cardiac effects. Cardiovasc. Drugs Ther. 6 (1992), 153–158.
42. 42 Reynolds, A.R., Hart, I.R., Watson, A.R., Welti, J.C., Silva, R.G., Robinson, S.D., Da Violante, G., Gourlaouen, M., Salih, M., Jones, M.C., et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat. Med. 15 (2009), 392–400.
43. 43 Oliveira-Ferrer, L., Hauschild, J., Fiedler, W., Bokemeyer, C., Nippgen, J., Celik, I., Schuch, G., Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J. Exp. Clin. Cancer Res., 27, 2008, 86.
44. 44 Stupp, R., Hegi, M.E., Gorlia, T., Erridge, S.C., Perry, J., Hong, Y.K., Aldape, K.D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 15 (2014), 1100–1108.
45. 45 Wong, P.P., Demircioglu, F., Ghazaly, E., Alrawashdeh, W., Stratford, M.R., Scudamore, C.L., Cereser, B., Crnogorac-Jurcevic, T., McDonald, S., Elia, G., et al. Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell 27 (2015), 123–137.
46. 46 Bergman, A.M., Pinedo, H.M., Peters, G.J., Determinants of resistance to 2’,2’-difluorodeoxycytidine (gemcitabine). Drug Resis. Updates 5 (2002), 19–33.
47. 47 Neff, T., Blau, C.A., Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp. Hematol. 24 (1996), 1340–1346.
48. 48 Sledge, G.W., Anti-vascular endothelial growth factor therapy in breast cancer: game over?. J. Clin. Oncol. 33 (2015), 133–135.
49. 49 Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D.D., Shalinsky, D.R., Thurston, G., Yancopoulos, G.D., et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165 (2004), 35–52.
50. 50 Pham, C.D., Roberts, T.P., van Bruggen, N., Melnyk, O., Mann, J., Ferrara, N., Cohen, R.L., Brasch, R.C., Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest. 16 (1998), 225–230.